PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 11.69M 10.16M 9.46M 8.68M 16.4M 1.12B 16.65M 112M 43.76M 556M 43.91M 42.94M 1.86B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 16.58M 14.41M 13.42M 12.32M 23.26M 1.58B 23.62M 158M 62.07M 788M 62.28M 60.91M 2.64B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/08/24	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/06/24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/06/24	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/01/24	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/12/23	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/05/23	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/05/23	PCL to Raise 36 Billion Won via Share Issuance	MT
23/03/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/12/22	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	352,666.67
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-88.11%	11.69M
VERACYTE, INC.	-22.52%	-18.18%	+95.94%	+79.19%	3.72B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-6.66%	+1.35%	+118.49%	+183.54%	3.59B
CAREDX, INC.	+14.72%	+17.69%	+257.69%	+288.19%	2.26B
BGI GENOMICS CO., LTD.	+3.44%	+4.55%	-27.34%	-35.28%	2.17B
IOVANCE BIOTHERAPEUTICS, INC.	-13.22%	-18.44%	+51.87%	-43.31%	1.82B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.67%	-2.81%	+195.95%	-45.02%	969M
SEEGENE, INC.	+6.96%	-1.82%	-7.40%	+21.17%	853M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.29%	+6.41%	-38.87%	-11.36%	511M
CURIOX BIOSYSTEMS CO., LTD	+7.90%	-3.22%	-0.27%	-	449M
Average	-1.24%	-2.92%	+64.61%	+38.78%	1.64B
Weighted average by Cap.	-5.11%	-3.72%	+95.62%	+89.14%

	2023	2024
Net sales	8.43B 5.86M 5.1M 4.75M 4.36M 8.23M 560M 8.35M 55.93M 21.95M 279M 22.03M 21.54M 935M	1.25B 867K 754K 702K 644K 1.22M 82.76M 1.24M 8.27M 3.25M 41.2M 3.26M 3.18M 138M
Net income	-20.32B -14.14M -12.29M -11.44M -10.5M -19.83M -1.35B -20.14M -135M -52.91M -672M -53.09M -51.92M -2.25B	-52.34B -36.41M -31.65M -29.46M -27.05M -51.08M -3.48B -51.87M -347M -136M -1.73B -137M -134M -5.8B
Net Debt	7.2B 5.01M 4.36M 4.06M 3.72M 7.03M 478M 7.14M 47.8M 18.76M 238M 18.82M 18.41M 799M	7.03B 4.89M 4.25M 3.96M 3.63M 6.86M 467M 6.97M 46.65M 18.31M 232M 18.37M 17.97M 779M